Radnostix, Inc.

Radnostix, Inc. (formerly International Isotopes Inc., established 1995) is a domestic supplier of radioisotope products, medical devices, and nuclear medicine infrastructure solutions. The company operates across five primary business segments: Calibration & Reference Products (radioactive standards and quality control solutions for nuclear medicine and industrial calibration); Theranostics Products (I-131, Tb-161, and theranostic precursors for targeted radionuclide therapy); Co-60 & High Energy Products (high-activity cobalt-60 and other industrial and medical sources); Medical Devices & Equipment (shielding solutions, instruments, and lab equipment for nuclear medicine facilities); and Bulk Isotope Sales for manufacturers, research institutions, and radiopharmaceutical production. The company recently achieved second-highest annual revenue in its history (FY2025), with 21% growth in calibration and reference products driven by PET-focused innovation. Radnostix operates under regulated frameworks including NRC licensing and maintains exclusive North American distribution agreements for advanced radiation monitoring and measurement instrumentation. The company is actively engaged in facility upgrades, medical device pipeline advancement, and infrastructure investments to support long-term growth in the radioisotope and theranostics market.